Curis Propels Two Proprietary Drugs Forward In Plan To Retain Value
This article was originally published in The Pink Sheet Daily
Executive Summary
Cancer drug developer Curis held its first R&D day Oct. 3, a sign its early pipeline is maturing. The company outlined development plans for two proprietary drugs, an IAP inhibitor and a PI3K/HDAC inhibitor, both in early clinical development. As for partnering those assets, CEO Passeri said the company is looking to retain more value for them than it did for Erivedge.